CRIS Current Research Information System

MANCUSO, KATIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.209
NA - Nord America 3.883
EU - Europa 2.528
SA - Sud America 303
AF - Africa 293
Continente sconosciuto - Info sul continente non disponibili 256
OC - Oceania 10
Totale 12.482
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.755
VN - Vietnam 1.524
CN - Cina 1.335
SG - Singapore 1.176
IT - Italia 880
GB - Regno Unito 331
HK - Hong Kong 280
DE - Germania 249
KR - Corea 233
BR - Brasile 228
BD - Bangladesh 205
SE - Svezia 198
NL - Olanda 179
IN - India 169
FR - Francia 163
CI - Costa d'Avorio 117
FI - Finlandia 116
RU - Federazione Russa 89
JP - Giappone 74
IE - Irlanda 72
ZA - Sudafrica 63
CA - Canada 52
SC - Seychelles 47
UA - Ucraina 35
AR - Argentina 33
TG - Togo 33
MX - Messico 32
BG - Bulgaria 31
PH - Filippine 31
AT - Austria 30
TH - Thailandia 30
BE - Belgio 27
ES - Italia 27
EE - Estonia 21
PL - Polonia 21
TW - Taiwan 21
ID - Indonesia 20
IQ - Iraq 18
JO - Giordania 17
CH - Svizzera 16
CO - Colombia 12
JM - Giamaica 12
SA - Arabia Saudita 11
AU - Australia 9
EC - Ecuador 9
PK - Pakistan 9
TR - Turchia 9
NG - Nigeria 8
CZ - Repubblica Ceca 6
RO - Romania 6
SV - El Salvador 6
UZ - Uzbekistan 6
CL - Cile 5
CR - Costa Rica 5
DZ - Algeria 5
HN - Honduras 5
IR - Iran 5
LT - Lituania 5
MY - Malesia 5
NI - Nicaragua 5
VE - Venezuela 5
EG - Egitto 4
GR - Grecia 4
GT - Guatemala 4
MA - Marocco 4
NP - Nepal 4
PT - Portogallo 4
AE - Emirati Arabi Uniti 3
KE - Kenya 3
KZ - Kazakistan 3
LB - Libano 3
MT - Malta 3
OM - Oman 3
PE - Perù 3
PY - Paraguay 3
RS - Serbia 3
TN - Tunisia 3
UY - Uruguay 3
BO - Bolivia 2
BS - Bahamas 2
CY - Cipro 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GH - Ghana 2
KG - Kirghizistan 2
LV - Lettonia 2
MD - Moldavia 2
NO - Norvegia 2
PS - Palestinian Territory 2
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
ET - Etiopia 1
GP - Guadalupe 1
HU - Ungheria 1
IL - Israele 1
KH - Cambogia 1
Totale 12.216
Salva come PNG Salva come JPEG
Città #
Singapore 829
Ashburn 476
Hefei 475
Ho Chi Minh City 422
Hanoi 334
San Jose 303
Hong Kong 267
Chandler 260
Southend 234
Bologna 222
Seoul 220
Dallas 211
Fairfield 199
Beijing 119
Abidjan 117
New York 114
Ann Arbor 113
Woodbridge 107
Council Bluffs 105
Seattle 98
Santa Clara 91
Wilmington 88
Houston 86
Los Angeles 85
Helsinki 77
Lauterbourg 75
Boardman 70
Dublin 68
Milan 67
Cambridge 62
Haiphong 59
Tokyo 59
Dong Ket 57
Princeton 56
Bengaluru 46
São Paulo 46
Buffalo 42
Frankfurt am Main 40
Hyderabad 38
Munich 36
Da Nang 35
Lomé 33
Rome 33
Johannesburg 30
Lappeenranta 30
Sofia 29
Turin 29
Guangzhou 27
Amsterdam 26
Bremen 26
Brussels 25
Chicago 22
Florence 22
Westminster 22
Vienna 21
Atlanta 20
Can Tho 20
Jinan 20
Padova 20
Redondo Beach 20
Berlin 19
Dongguan 18
Fabriano 18
London 18
Nanjing 18
Nuremberg 18
Shenzhen 18
Amman 17
Biên Hòa 17
Ninh Bình 17
Phoenix 17
Quận Bình Thạnh 17
Shanghai 17
Changsha 16
Mexico City 16
San Diego 16
Brooklyn 15
Hải Dương 15
Thái Nguyên 15
Ha Long 14
Jacksonville 14
Redmond 14
Tianjin 14
Tongling 14
San Francisco 13
Warsaw 13
Jakarta 12
Paris 12
Toronto 12
Zhengzhou 12
Montreal 11
Nanchang 11
Naples 11
Bắc Giang 10
Bắc Ninh 10
Falkenstein 10
Orem 10
Redwood City 10
Shenyang 10
Wuhan 10
Totale 7.552
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 719
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 359
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 272
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 251
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 250
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 238
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 237
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 223
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 222
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 221
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 213
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 213
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 213
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 213
A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role? 212
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 205
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 205
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 202
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 201
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 196
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 194
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 192
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 188
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 184
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 182
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 182
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 180
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 180
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 178
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 177
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 176
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 172
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma 170
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 166
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 165
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 162
Multidisciplinary Management of Sternal Osteomyelitis Due to Klebsiella aerogenes after Open Heart Surgery in a Patient with Multiple Myeloma: A Case Report and Discussion of the Literature 162
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 160
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 159
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents 155
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 155
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 146
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 146
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 142
Role of consolidation therapy in transplant eligible multiple myeloma patients. 139
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 136
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 134
Pomalidomide combinations are a safe and effective option after daratumumab failure 133
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 131
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients 130
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 127
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 126
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 125
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 124
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma 123
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients 120
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 113
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study 111
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight 102
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS 101
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 101
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing 98
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 97
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 97
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 94
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 92
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial 92
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 87
A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide 81
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma 78
Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy 78
Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma 77
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients 64
Belamaf: Is Renal Toxicity an Overlooked Side Effect? 64
VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation 62
Correction: Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma 61
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study 46
Totale 12.482
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.573
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022641 0 38 42 61 57 21 16 50 29 84 121 122
2022/2023962 78 135 29 145 72 91 26 55 158 26 95 52
2023/2024442 28 40 24 35 25 88 14 87 11 35 37 18
2024/20251.867 110 167 153 135 127 66 133 64 55 222 214 421
2025/20266.609 575 1.130 569 578 507 312 511 250 1.086 451 327 313
2026/2027468 215 253 0 0 0 0 0 0 0 0 0 0
Totale 12.482